Watson Pharmaceuticals Inc
Article Abstract:
Watson Pharmaceuticals Inc.'s transdermal therapy product, Oxytro l, has been approved by the FDA. Stock is ranked to outperform market averages for the next 6 - 12 months but little appeal for capital appreciation potential for 3 - 5 years.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Government regulation, Pharmaceutical industry, Licensing agreements, Licensing, certification and accreditation, Watson Pharmaceuticals Inc., WPI, United States. Food and Drug Administration, Oxytrol (Transdermal patch)
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
WebMD
Article Abstract:
WebMD posted reasonable profits in 2002 and is expected to have 10-12-% revenue growth in 2003. Although shares are Timely, they are best held by aggressive accounts.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
On-Line Information Services, Database Vendors, Information retrieval services, Database industry, WebMD Inc., WBMD
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Finance, Company investment, Investments, Statistics, Securities, Company sales and earnings, Company earnings/profit, Company securities, Company business forecast/projection, Company forecasts
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.